IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
Surbhi Sidana(Palo Alto University), Morie A. Gertz(Medical University of South Carolina), Francis K. Buadi, Rebecca L. King(Mayo Clinic in Arizona), Nelson Leung(WinnMed), Robert A. Kyle(Mayo Clinic), Shaji Kumar(Mayo Clinic), Prashant Kapoor, Daniel P. Larson(Mayo Clinic in Arizona), David Murray(Unknown), Ellen D. McPhail(Mayo Clinic), Stephen M. Ansell(Mayo Clinic), Surendra Dasari(Mayo Clinic in Arizona), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Patricia T. Greipp(Mayo Clinic), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Angela Dispenzieri(Mayo Clinic), Rong He(Mayo Clinic), Marina Ramı́rez-Alvarado(WinnMed)
Cited by 56
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k